Post HDLc Q4 (≥1.64 mmol/L) versus Q1 (<1.20 mmol/L): 0.75 (0.58, 0.97)* Post HDLc Q4 (≥1.64 mmol/L) versus Q1 (<1.20 mmol/L) BMI ≥25 kg/m2: 0.43 (0.28, 0.67)†
|
Post (no HRT) BMI (≥30.0 versus <25 kg/m2): 1.31 (1.08, 1.59); Pre hip circumference (≥108.0 versus <94.0 cm): 1.70 (1.05, 2.77)*; Post hip circumference (≥108.0 versus <94.0 cm): 1.56 (1.12, 2.17); Post weight (≥75 versus >56.8 kg): cancer risk 1.65 (1.32, 2.08) |
Pre BMI (Q4 ≥24.4 kg/m2 versus Q1 <18.5 kg/m2): 0.61 (0.42, 0.89)*; Post BMI (Q4 ≥25.1 kg/m2 versus Q1 <20.0 kg/m2): 1.21 (0.96, 1.52); Pre weight Q4 (>65 kg) versus Q1 (<54 kg): 0.57 (0.42, 0.98)*
|
Post Norwegian women n = 13,519; pre women n = 25, 304; prospective population-based cohort study |
Post women n = 103,344; pre women n = 73,542; prospective population-based cohort study |
Post French women n = 42,357; pre women n = 20,839; prospective cohort study |
Age; height; BMI; serum cholesterol; recreational activity; occupational activity; parity; menopausal status; country of residence |
Study center; age; education; smoking; alcohol consumption; parity; age at first pregnancy; age at menarche; current pill use; BMI |
Family history of breast cancer in first degree relatives; age at menarche; age at first birth; benign breast disease; alcohol consumption; education; marital status; physical activity (BMI not controlled for pre weight) |
Cancer-free and alive 1 year after the study started |
|
|
Pregnancy during the survey; primary amenorrhea |
Surgical menopause or uncertain of menopause state |
Undefined menopausal status; women who never menstruated; cancer other than basal cell carcinoma |
HDLc with BMI in pre women |
BMI (pre); waist circumference; waist/hip ratio; height; weight |
Waist/hip ratio; hip circumference; height; breast circumference; waist circumference; thorax circumference |